Kaletra Tablet, Film Coated
NDC Package 0074-4014-12
Package Information
Kaletra (lopinavir and ritonavir) tablets is kALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older. This formulation utilizes a tablet, film coated delivery system. Marketed by Abbvie Inc., this product is identified by NDC 0074-4014 and is authorized under FDA application NDA021906.
Identification & Billing
- RxCUI: 311369 - lopinavir 80 MG / ritonavir 20 MG in 1 mL Oral Solution
- RxCUI: 311369 - lopinavir 80 MG/ML / ritonavir 20 MG/ML Oral Solution
- RxCUI: 311369 - lopinavir 400 MG / ritonavir 100 MG per 5 ML Oral Solution
- RxCUI: 311369 - lopinavir 80 MG / ritonavir 20 MG per 1 ML Oral Solution
- RxCUI: 597730 - lopinavir 200 MG / ritonavir 50 MG Oral Tablet
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 1A2 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2B6 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C19 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2C9 Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 2D6 Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inducers - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitor - [EPC] (Established Pharmacologic Class)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A4 Inhibitors - [MoA] (Mechanism of Action)
- HIV Protease Inhibitors - [MoA] (Mechanism of Action)
- Organic Anion Transporting Polypeptide 1B1 Inhibitors - [MoA] (Mechanism of Action)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- Protease Inhibitor - [EPC] (Established Pharmacologic Class)
- UDP Glucuronosyltransferases Inducers - [MoA] (Mechanism of Action)
Regulatory & Marketing
Hierarchy Structure
- 0074 - Abbvie Inc.
- 0074-4014 - Kaletra
- 0074-4014-12 - 120 TABLET, FILM COATED in 1 BOTTLE
- 0074-4014 - Kaletra
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0074-4014-12 identifies a specific commercial package of 120 tablet, film coated in 1 bottle of Kaletra, a human prescription drug labeled by Abbvie Inc.. This tablet, film coated is formulated for oral use and contains lopinavir; ritonavir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Abbvie Inc. on April 08, 2020. The current certification is valid through December 31, 2027.
How is this Abbvie Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00074401412. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.